Targeted-cancer therapies are a hot topic now days as these powerful medications have become more mainstream. These are some of the most advanced cancer-fighting drugs in history, and they have rapidly changing the face of cancer research. Thanks to the medication’s ability to bind to cancer cells, the body’s healthy cells can be spared much more proficiently. This means that cancer patents won’t have to deal with the sickening side effects that come along with cancer treatments. One of the top organizations in the world that specializes in these therapies is Seattle Genetics. This particular company has been in business since 1998, and it has made a huge impact on society.
Seattle Genetics is located in Bothell, Washington, and it was founded by Dr. Clay Siegall. If you have a general amount of knowledge in this subject, then you’ve probably heard about this extraordinary man. Dr. Siegall has worked in this business for more than three decades. He’s an “old guard” of the industry because he believes in doing copious amounts of research to achieve a solution. In addition to that, this man believes in combining drug development and scientific innovation. Seattle Genetics’ flagship drug is now being used in over 60 countries worldwide. This drug is known as ADCETRIS, and it’s one of the top cancer-fighting drugs in history. As of 2018, ADCETRIS has generated more than $350 million in revenue. It is one of the main reasons to why Seattle Genetics’ stock has tripled over the past five years.
“I got into this business because my father suffered from cancer,” said Siegall. He was only a college student when his father became ill, and he saw how devastating cancer could be to the human body. “Previous cancer treatments were extremely harsh,” said Siegall. Ever since that moment in time, he has been putting in work to help save as many lives as possible. Dr. Clay Siegall is definitely the heart and soul of cancer research.